Idogen: First patient enrolled in IDO 8 phase l/lla-trial - Redeye

Redeye endorses yesterday’s news that Idogen has enrolled the first patient in its phase l/lla-trial. This marks a concrete step forward for Idogen, which is now a clinical-stage entity. Each patient enrolled is important, as information will be gathered sequentially, revealing initial data points on the treatment’s safety and potential efficacy.

Länk till analysen i sin helhet: https://www.redeye.se/research/858043/idogen-first-patient-enrolled-in-phase-l-lla-trial?utm_source=finwire&utm_medium=RSS